01 9Vraylar
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 951
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 1,728
2020 Revenue in Millions : 951
Growth (%) : 82
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 2,038
2021 Revenue in Millions : 1,728
Growth (%) : 18
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 2,759
2022 Revenue in Millions : 2,038
Growth (%) : 35
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 3,267
2023 Revenue in Millions : 2,759
Growth (%) : 18
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 289
2016 Revenue in Millions : 94
Growth (%) : 206
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 487
2017 Revenue in Millions : 289
Growth (%) : 69%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 858
2018 Revenue in Millions : 487
Growth (%) : 76
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 94
2015 Revenue in Millions : Not Reported
Growth (%) : New Launch
